BioSpace News Archive

Lineage Cell Therapeutics, Inc. reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, reported financial results for the first quarter ended March 31, 2024.

Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.

AnaptysBio, Inc. announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab in patients with generalized pustular psoriasis, a severe orphan disease that is potentially life-threatening if left untreated.

Hangzhou Qihan Biotech Co., Ltd., an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced the appointment of Mr. Yingyong Xu as the Chief Medical Officer.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.

Zynex, Inc. announced it will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held May 14-15, 2024.

Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company.

The U.S. Food and Drug Administration issued final guidance to provide the medical device industry clarity on the definition of “remanufacturing” for reusable devices needing maintenance or repair.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family companies Napo Pharmaceuticals (“Napo”) and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar’s novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults.